Key Developments: Fresenius Medical Care AG & Co KGaA (FMEG.DE)

FMEG.DE on Xetra

61.61EUR
11:35am EST
Price Change (% chg)

€1.06 (+1.75%)
Prev Close
€60.55
Open
€60.68
Day's High
€61.75
Day's Low
€60.68
Volume
707,431
Avg. Vol
908,948
52-wk High
€61.75
52-wk Low
€46.69

Search Stocks

Latest Key Developments (Source: Significant Developments)

Fresenius Medical Care AG & Co KGaA announces agreement to acquire Cogent Healthcare
Wednesday, 12 Nov 2014 07:00pm EST 

Fresenius Medical Care AG & Co KGaA:Announces agreement to acquire Cogent Healthcare.Says expects Cogent to generate approx. $250 million in revenue in 2015.Investment will be financed through available cash.Expect the transaction, which remains subject to regulatory clearance, to close within the quarter.Financial terms of the acquisition not disclosed.  Full Article

Fresenius Medical Care AG & Co KGaA announces agreement to acquire Cogent Healthcare
Wednesday, 12 Nov 2014 07:00pm EST 

Fresenius Medical Care AG & Co KGaA:Announces that Sound Physicians Inc. (Sound) has entered into agreement to acquire Cogent Healthcare (Cogent) with more than 650 providers, who offer hospitalist and intensivist services to more than 80 hospitals throughout.Fresenius Medical Care is majority shareholder in Sound.Parties involved agreed not to disclose financial terms of the acquisition.  Full Article

Fresenius Medical Care AG & Co KGaA reiterates FY 2014 outlook
Tuesday, 4 Nov 2014 01:23am EST 

Fresenius Medical Care AG & Co KGaA:Confirms guidance for full FY 2014.Expects revenue to be at around $15.2 billion in FY 2014, translating into growth rate of around 4 pct.Says this outlook excludes revenue of about $500 million from acquisitions.Says net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to be unchanged between $1.0 billion and $1.05 billion in FY 2014.FY 2014 revenue estimate $15.474 billion - Thomson Reuters I/B/E/S.  Full Article

Fresenius Medical Care AG & Co KGaA successfully places senior notes
Friday, 24 Oct 2014 10:30am EDT 

Fresenius Medical Care AG & Co KGaA:Says successfully placed U.S. dollar senior unsecured notes in the amount of $500 million due 2020 with a coupon of 4.125 pct and in the amount of $400 million due 2024 with a coupon of 4.75 pct.Net proceeds are intended to be used to repay short-term borrowings under the 2012 Credit Agreement as well as other short term debt, and for acquisitions and general corporate purposes.  Full Article

Fresenius Medical Care AG & Co KGaA to acquire National Cardiovascular Partners
Wednesday, 22 Oct 2014 11:44am EDT 

Fresenius Medical Care AG & Co KGaA:Says to acquire National Cardiovascular Partners.Parties involved agreed not to disclose the financial terms of the acquisition.Expects NCP to generate in excess of $200 million in revenue in 2015 and expects the investment to be accretive to earnings in the first year after closing.Investment will be financed through available cash and committed credit facilities, supplemented by additional debt financing.  Full Article

Fresenius Medical Care AG & Co KGaA to issue 400 million euros convertible bonds
Tuesday, 16 Sep 2014 01:39am EDT 

Fresenius Medical Care AG & Co KGaA:Intends to place equity-neutral convertible bonds due 2020 in aggregate principal amount of 400 million euros.Says final maturity date of the bonds is Jan. 31, 2020.Says bonds to be issued and redeemed at 100 pct of their principal amount.Says bonds to be offered with coupon between 0.125 pct - 1.125 pct per annum.Says bonds to be issued with conversion premium of 35 pct above share reference price.Says placement to be executed via accelerated bookbuilding.Says BofA Merrill Lynch is acting as Sole Global Coordinator in relation to offering and together with Commerzbank AG and Societe Generale Corporate & Investment Banking as Joint Bookrunner and Lead Manager.  Full Article

Fresenius Medical Care AG & Co KGaA confirms FY 2014 outlook
Thursday, 31 Jul 2014 01:22am EDT 

Fresenius Medical Care AG & Co KGaA:Confirms guidance for full FY 2014.Expects revenue to be at around $15.2 billion in FY 2014, translating into growth rate of around 4 pct.Says this outlook excludes revenue of about $500 million from acquisitions.Says net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to be unchanged between $1.0 billion and $1.05 billion in FY 2014.FY 2014 revenue estimate $15.29 billion - Thomson Reuters I/B/E/S.  Full Article

Fresenius Medical Care AG & Co KGaA and Aetna Inc collaborate to provide coordinated care management for end stage renal disease patients
Tuesday, 10 Jun 2014 06:00am EDT 

Fresenius Medical Care AG & Co KGaA and Aetna Inc:Collaborative care model designed to improve quality of care for Aetna's Medicare Advantage members who have end stage renal disease, while lowering health care costs.  Full Article

Fresenius Medical Care AG & Co KGaA confirms its FY 2014 guidance in line with analysts estimates
Tuesday, 6 May 2014 01:38am EDT 

Fresenius Medical Care AG & Co KGaA:Expects revenue to be at around $15.2 billion in 2014, translating into a growth rate of around 4 pct, I/B/E/S Estimates revenue of $15.281 billion for 2014.Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to be between $1.0 billion and $1.05 billion in 2014, I/B/E/S Estimates for 2014 net income of $1.120 billion.Expects to spend around $900 million on capital expenditures in 2014, I/B/E/S Estimates capex of $874.62 million for 2014.  Full Article

Fresenius Medical Care AG & Co KGaA and Joslin Diabetes Center Inc to work together to improve health of patients with diabetic kidney disease
Tuesday, 15 Apr 2014 02:28am EDT 

Fresenius Medical Care AG & Co KGaA:Says with Joslin Diabetes Center, Inc to jointly develop renal care programs in select Joslin Affiliated Centers for patients with diabetic kidney disease (DKD).Fresenius Medical Care and Joslin to jointly develop clinical guidelines and care delivery systems to manage high blood pressure, glucose, and nutrition in patients with DKD.In addition, organizations to help educate patients as they prepare for possibility of end stage renal disease (ESRD) and necessity for dialysis or kidney transplantation.  Full Article

China halts anti-dumping probe into EU, Japan dialysis kit makers

SHANGHAI - China has halted an anti-dumping investigation into European and Japanese makers of blood dialysis equipment, ending a six-month probe that had extended to the Chinese market leader, Germany's Fresenius Medical Care (FMC) AG & Co KGaA.

Search Stocks